Loading...
This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.
Click here to view the deleted recordThis document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Internationally Recognized Certificates of Compliance
(IRCC)
last updated: 20 Sep 2019
ABSCH-IRCC-IN-247740-1
Competent National Authority:National Biodiversity Authority ()5th Floor, TICEL Biopark, CSIR Road, TaramaniChennai, Tamilnadu
600 113, IndiaPhone: +91 44 2254 2777,Fax: +91 44 2254 1200,Website: http://www.nbaindia.org,
India/NBA/Appl/9/1517
Application in Form-III for seeking approval for the invention on "Antiviral formulation for rabies and encephalitis causing viruses from Plants" for obtaining IP Rights in India
Indian Patent Application Number: 3672/MUM/2013
18 Dec 2017
Yes
Competent National Authority:National Biodiversity Authority ()5th Floor, TICEL Biopark, CSIR Road, TaramaniChennai, Tamilnadu
600 113, IndiaPhone: +91 44 2254 2777,Fax: +91 44 2254 1200,Website: http://www.nbaindia.org,
Confidential information
Person:Dr Rajesh Kumar GanjhuRow House No.3, S.No.1/1/1, Laxminagar, Pimple Gurav,Pune, Maharashtra
411 061, IndiaPhone: +91 9422556869,Fax:Email: rajeshganjhu@gmail.com,Website:
Confidential information
Yes
1. The user shall notify the NBA within 60 days from the date of grant of IPR.
2. If the user himself commercializes the process/product/innovation, the monetary sharing shall be 0.2% on the annual gross ex-factory sale minus government taxes.
3. The user shall inform the NBA about any commercialization made on the IP Rights granted.
4. The user shall submit annual report to NBA as per the terms and conditions agreed upon.
For obtaining IP Rights on the Invention on “Antiviral formulation for rabies and encephalitis causing viruses from plants" in India
Biological Resources:
Shalparni - Desmodium gangeticum (root)
Confidential information
- Commercial
1. If the user assigns/licenses the process/product/innovation to a third party for commercialization, the user shall pay to NBA 3.0% of the fee received (in any form including the license / assignee fee) and 2.0% of the royalty amount received annually from the assignee/licensee.
2. In case the user assigns or transfer the IPR in whole or in part to any person, whether voluntarily or involuntarily, the user undertakes to attach this agreement as an appendix to the assignment instrument which shall be binding upon such person.
| Unique identifier | Status | Date |
|---|---|---|
| ABSCH-IRCC-IN-247740-1 |
REVOKED
OLD VERSION
PUBLISHED
DELETED
|
Sujata Arora (sujata@nic.in)
20 Sep 2019 11:47 on 20 Sep 2019 11:47
|
